Fast Track To Hope: FDA Advances New AlloNK Therapy For Lupus Nephritis Treatment
The Food & Drug Administration (FDA) has recently given Fast Track status to a new therapy called AlloNK® (also known as AB-101), which is being studied as a potential treatment for lupus nephritis, a type of kidney disease caused by lupus. AlloNK is made from natural killer (NK) cells, a part of our immune system, […]
Fast Track To Hope: FDA Advances New AlloNK Therapy For Lupus Nephritis Treatment Read More »